Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma Publisher Pubmed



Eskian M1, 2 ; Khorasanizadeh M1, 2 ; Zinzani PL3 ; Illidge TM4 ; Rezaei N1, 5, 6
Authors

Source: International Reviews of Immunology Published:2019


Abstract

Radioimmunotherapy (RIT) is a novel strategy for treating non-Hodgkin lymphoma (NHL). Several studies have shown the promising results of using RIT in NHL, which have led to FDA approval for two RIT agents in treating low grade NHL. In spite of these favorable results in low-grade NHL, most of the aggressive or relapsed/refractory NHL subjects experience relapses following RIT. Although more aggressive treatments such as myeloablative doses of RIT followed by stem cell transplantation appear to be able to provide a longer survival for some patients these approaches are associated with significant treatment-related adverse events and challenging to deliver in most centers. Therefore, it seems reasonable to develop treatment approaches that enhance the efficiency of RIT, while reducing its toxicity. In this paper, novel methods that improve the efficiency of RIT and reduce its toxicity through various mechanisms are reviewed. Further clinical development of these methods could expand the NHL patient groups eligible for receiving RIT, and even extend the use of RIT to new indications and disease groups in future. © 2019, © 2019 Taylor & Francis.
1. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
2. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
Experts (# of related papers)
Other Related Docs
5. Immunopathology and Immunotherapy of Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
6. Immunopathology and Immunotherapy of Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
12. Anti-Cd20 Antibody Treatment for B-Cell Malignancies, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2 (2023)
18. Cancer Immunology: Bench to Bedside Immunotherapy of Cancers, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers (2015)
19. Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma, Expert Review of Anticancer Therapy (2021)